Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice

American Journal of Clinical Nutrition

Volumn 84, Issue 2, 2006, Pages 312-321

  Duivenvoorden, Ilse ^a,b   Voshol, Peter J ^a,b   Rensen, Patrick C N ^a,b   Van Duyvenvoorde, Wim ^a   Romijn, Johannes A ^b   Emeis, Jef J ^a   Havekes, Louis M ^a,b   Nieuwenhuizen, Willem F ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

APOE*3Leiden mice; Cholesterol; Free fatty acids; Sphingolipids; Steatosis; Triacylglycerol

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLOID; APOLIPOPROTEIN E3; CHOLESTEROL; CHOLESTEROL ESTER; FATTY ACID; MESSENGER RNA; PHYTOSPHINGOSINE; RNA; SPHINGOLIPID; TRIACYLGLYCEROL; APOLIPOPROTEIN E; APOLIPOPROTEIN E3 (LEIDEIN); VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; FATTY LIVER; FEMALE; GENE EXPRESSION; HEPATITIS; LIPOGENESIS; LIPOLYSIS; MOUSE; NONHUMAN; NUTRITIONAL ASSESSMENT; PLASMA CLEARANCE; PROPHYLAXIS; ANIMAL; BLOOD; CHEMISTRY; CHOLESTEROL INTAKE; ENZYMOLOGY; FECES; GENETICS; INTESTINE ABSORPTION; LIPID METABOLISM; LIVER; METABOLISM; PHYSIOLOGY; RANDOMIZATION; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, DIETARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FECES; FEMALE; GENE EXPRESSION; INTESTINAL ABSORPTION; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, TRANSGENIC; RANDOM ALLOCATION; RNA; SPHINGOLIPIDS; TRIGLYCERIDES;

EID: 33748427104     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.1.312     Document Type: Article

References (40)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
2. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.
3. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994; 93:1403-10.
4. Kleemann R, Princen HM, Emeis JJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-74.
5. Verschuren L, Kleemann R, Offerman EH, et al. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2005;25:161-7.
6. Zambon A, Hashimoto SI, Brunzell JD. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J Lipid Res 1993;34:1021-8.
7. Koopman J, Maas A, Rezaee F, et al. Fibrinogen and atherosclerosis: a study in transgenic mice. Fibrinolysis Proteolysis 1997;11(suppl):19-21.
8. Borgstrom B. Quantitative aspects of the intestinal absorption and metabolism of cholesterol and beta-sitosterol in the rat. J Lipid Res 1968;9:473-81.
9. Wang DQ, Carey MC. Measurement of intestinal cholesterol absorption by plasma and fecal dual-isotope ratio, mass balance, and lymph fistula methods in the mouse: an analysis of direct versus indirect methodologies. J Lipid Res 2003;44:1042-59.
10. Post SM, de Crom R, van Haperen R, van Tol A, Princen HM. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. Arterioscler Thromb Vasc Biol 2003;23:892-7.
11. Borensztajn J, Rone MS, Kotlar TJ. The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339. Biochem J 1976;156:539-43.
12. Aalto-Setala K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889-900.
13. Jong MC, Dahlmans VE, van Gorp PJ, et al. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol 1996;16:934-40.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
15. Li X, Catalina F, Grundy SM, Patel S. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J Lipid Res 1996;37:210-20.
16. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1995;1254:77-88.
17. Rensen PC, Herijgers N, Netscher MH, Meskers SC, van Eck M, van Berkel TJ. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 1997;38:1070-84.
18. Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 2001;42:1578-85.
19. Chomczynski P Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
20. Bloks VW, Plosch T, van Goor H, et al. Hyperlipidemia and atherosclerosis associated with liver disease in ferrochelatase-deficient mice. J Lipid Res 2001;42:41-50.
21. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
22. Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol 2004;24:768-74.
23. Heijboer AC, Donga E, Voshol PJ, et al. Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice. J Lipid Res 2005;46:582-8.
24. Bandsma RH, Van Dijk TH, Harmsel AA, et al. Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. J Biol Chem 2004;279:8930-7.
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-7.
26. Havekes LM, de Wit EC, Princen HM. Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity. Biochem J 1987;247:739-46.
27. Post SM, de Wit EC, Princen HM. Cafestol, the cholesterol-raising factor in boiled coffee, suppresses bile acid synthesis by downregulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase in rat hepatocytes. Arterioscler Thromb Vasc Biol 1997;17:3064-70.
28. Rensen PC, Jong MC, van Vark LC, et al. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem 2000;275:8564-71.
29. Nyberg L, Nilsson, A, Lundgren P, Duan R. Localization and capacity of sphingomyelin digestion in the rat intestinal tract. Nutr Biochem 1997;8:112-8.
30. Nyberg L, Duan RD, Nilsson A. A mutual inhibitory effect on absorption of sphingomyelin and cholesterol. J Nutr Biochem 2000;11:244-9.
31. Erpecum KJ, Carey MC. Influence of bile salts on molecular interactions between sphingomyelin and cholesterol: relevance to bile formation and stability. Biochim Biophys Acta 1997;1345:269-82.
32. Holopainen JM, Metso AJ, Mattila JP, Jutila A, Kinnunen PK. Evidence for the lack of a specific interaction between cholesterol and sphingomyelin. Biophys J 2004;86:1510-20.
33. Volger OL, van der Boom H, de Wit EC, et al. Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2001;21:1046-52.
34. Xiang SQ, Cianflone K, Kalant D, Sniderman AD. Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. J Lipid Res 1999;40:1655-63.
35. Van Veldhoven PP, Mannaerts GP, Declercq P, Baes M. Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)? Cell Signal 2000;12:475-9.
36. Kim H, Haluzik M, Asghar Z, et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 2003;52:1770-8.
37. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001;50:411-7.
38. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005;128:627-35.
39. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005;5:287-95.
40. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.